FDA Expands CAPVAXIVE Pediatric Use - Poll - MDSpire

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

  • By

  • Kathryn Wighton

  • June 18, 2026

  • 2 min

Share

Original Source(s)

FDA Expands CAPVAXIVE Pediatric Use

  • by Kathryn Wighton

  • June 18, 2026

Related Content

FDA Expands OTC CGM Access to Children

The device was previously cleared for adults aged 18 years and older in March 2024.

Local, State, and National Efforts That Support Influenza Surveillance—From the Ground Up

Editorial: Understanding oral health challenges in pediatric and adult cancer care